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Design of functionalized gold nanoparticle
probes for computed tomography imaging
Alessandro Silvestria,b†, Vanessa Zambellic†, Anna M. Ferrettia,
Domenico Salernoc, Giacomo Bellanic* and Laura Politoa*
The development of new molecules able to efficiently act as long-circulating computed tomography (CT) contrast
agents is one of the most crucial topics in the biomedical field. In the last years, the chance to manipulate materials
at the nano-size level gave new boost to this research, with the specific aim to design innovative nanoprobes. Gold
nanoparticles (AuNPs) have showed unique X-rays attenuation properties which, combined with their easy surface
functionalization, makes them ideal candidates for the next generation of contrast agents. In this paper, we present
a rational and facile approach to synthesize engineered and water-stable AuNPs, achieving concentrated colloidal
solution with high Hounsfield Units (HU). An accurate control of reagents ratio allowed us to design AuNPs with
different shapes, from symmetrical to anisotropic morphology, in a convenient ‘one-pot’ fashion. Their activity as
efficient and reliable CT contrast agents has been evaluated and compared. Moreover, glucosamine-functionalized
gold nanoparticles have been developed ([Au] = 31.20mg/mL; HU=2453), in order to obtain a CT contrast agent able
to combine spatial resolution with metabolic information. Copyright © 2016 John Wiley & Sons, Ltd.
Additional supporting information may be found in the online version of this article at the publisher’s web site.
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1. INTRODUCTION
Computed tomography (CT) is a widespread non-invasive medi-
cal imaging technique, characterized by good resolution, high
efficiency and low cost (1,2). In contrast with other techniques,
such as Positron Emission Tomography (PET), CT scan has a lower
sensitivity and lack of the ability to track specific metabolic
pathways (e.g., glucose metabolism). In some instances, due to
the lack of natural contrast from tissues, it can be necessary to
provide contrast with exogenous agents, to acquire more
detailed information about the regions of interest. Nowadays,
the most widespread CT contrast agents are hydrophilic poly-
iodinated compounds, characterized by a quick renal clearance
and a good vascular permeability (3). Nevertheless, these agents
carry drawbacks in clinical use, primarily related to renal toxicity,
allergic reactions and other side effects (4). Even if these limita-
tions are rare events, in the last years efforts have been devoted
to the development of new CT contrast agents based on
nano-materials (5,6). The possibility of manipulating nano-sized
materials tuning their features, makes nanotechnology an
exciting field of development for ‘smart’ contrast agents able
to circulate for prolonged period in the blood pool and to
actively target a specific site. Among the candidates as next
generation CT contrast agents, gold nanoparticles play a crucial
role, thanks to their easy surface functionalization, high X-ray
absorption coefficient and good biocompatibility. To date,
various gold nanostructures have been synthesized and tested
as potential CT contrast agents, pointing out the high potential-
ity of this material (7–14). Some of the most important features
for well-tolerable contrast agents are their easy elimination by
the body, their prolonged circulation in the blood, and the lack
of toxicity. In this context, some papers reported the synthesis
of ultrasmall AuNPs, able to be cleared through renal excretion,
hence avoiding the detrimental accumulation of the metal in
organs (13,14). Moreover, in the attempt to use the minimal
amount of contrast agents, great efforts have been devoted to
surface functionalization, exploiting an active targeting to the
site of interest. Gold nanoparticles, in fact, can be stably
engineered at the surface, taking advantage of the strong soft-
soft interaction between sulfur and gold atoms. By exploiting
this chemistry, it is possible to load on the vast and available
surface area several active compounds, which can help the
selectivity of the contrast agents or even act as therapeutics.
Besides and before clinical use, these kinds of nanomaterials
can act as effective and powerful pre-clinical contrast nano-
agents. For these reasons, continuous improvements on reliable
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synthesis and biological evaluation of surface-coated AuNPs are
necessary.
Here, we report the synthesis of highly stable and functional-
ized gold nanoparticles with the aim of elucidating the main
factors involved in their in vivo bio-distribution. To achieve this
result, the surface coatings and the morphologies of the core
have been fine tuned. By modifying described procedures, gold
nanoparticles have been synthesized through a ‘one-pot’
methodology which allowed us to obtain functionalized
symmetrical or anisotropic nanoparticles by means of an
accurate modulation of the reagents ratio. Anisotropic nano-
particles, as star-shaped gold nanoparticles, are emerging as
innovative nanomaterials since they can be exploited as
multimodal contrast agents for CT imaging and surface
enhanced Raman spectroscopy (SERS) (15,16). Considering the
great interest towards anisotropic nanoparticles features (17),
we were particularly interested in a deeper evaluation of their
in vivo properties as CT contrast agents, depending on the
dimension and in a comparison with symmetric shaped nano-
particles. Heterobifunctional thiolated polyethylene glycols
(HS-PEG5000-COOH and HS-PEG5000-OMe) have been evaluated
as biocompatible polymers (18) to stabilize gold colloidal
solutions and to increase their circulation time in blood pool.
Then, taking advantage of the available carboxylic group of
HS-PEG5000-COOH, we developed a proof-of-principle
glucosamide-coated nano-tracer characterized by an active
targeting towards glucose uptake, and hence metabolic activity.
It is commonly known, in fact, that neoplastic and inflammatory
cells show enhanced dependence from the glycolitic pathway,
(also in aerobic conditions), resulting in an increased cellular
uptake of glucose (19,20). For this reason the metabolism of
2-deoxy-D-glucose is still extensively studied (21) and its
analogue 2-([18F]fluoro)-2-deoxy-D-glucose (2FDG) is widely
used as radiotracer in PET-CT, for the detection of tumours and
inflammatory sites (22,23). All functionalized AuNPs were
subjected to a full characterization by Transmission Electron
Microscopy (TEM), Inductively Coupled Plasma-Optical Emission
Spectrometers (ICP-OES), UV–vis spectroscopy and Dynamic
Light Scattering (DLS). The structural information obtained were
correlated with the results of the in vivo experiments, conducted
by means of micro-CT imaging, to evaluate PEGylated AuNPs
activity as X-ray contrast agents and the time course of their
systemic distribution.
2. RESULTS AND DISCUSSION
2.1. Synthesis and characterization of functionalized gold
nanoparticles
Up to date, a vast number of protocols to synthesize gold nano-
particles are available in literature (24). Nevertheless, the identifi-
cation and development of improved strategies for synthesizing
AuNPs is an extremely important and crucial step, tightly linked
with their final application, surface functionalization and
colloidal stability. Among the large pool of existing procedures
to produce AuNPs in aqueous environment (24,25), Turkevich
protocol (26) is the most common and flexible one and a
number of revised methods are reported (27). For example, in
2011 Schütz et al. reported a seed mediated procedure based
on Turkevich methodology to prepare water-stable gold
anisotropic nanoparticles (28). By modifying the protocol
described in this paper, we developed a ‘one-pot’ strategy to
obtain functionalized AuNPs with different core morphologies
(Fig. 1), using sodium citrate and hydroquinone as reducing
agents. This protocol allowed us to control the anisotropy of
the core without the addition of toxic templating agents such
as cetyl trimethylammonium bromide (CTAB). Moreover, the
procedure can afford the synthesis of a large quantity of
functionalized AuNPs, without the need to purify the intermedi-
ate citrate-stabilized nanoparticles. The selected ligands, in fact,
were added directly to the mixture, to stop and cap nanoparti-
cles’ growing. The general protocol required the seeds synthesis
by adding gold salts, pre-incubated with sodium citrate and
silver nitrate, to boiling water. The seeds formation is almost
immediate, but to ensure the complete reduction and enhance
the crystal uniformity, the reaction mixture was stirred for
45min at 100 °C before starting the growing step.
A pre-activated mixture of HAuCl4, AgNO3 and sodium citrate
was added to the cooled seeds mixture, followed immediately
by a solution of hydroquinone in order to grow the seeds. The
colloidal mixture was stirred at room temperature for 1 hour
before capping the nanoparticles by means of thiolated
polyethylene glycols addition. For our purpose, HS-PEG5000-COOH,
HS-PEG5000-OMe and HS-PEG5000-CONHGlucose [see Supporting
Information (SI)] were screened as ligands. A PEG coating
guaranteed the indispensable colloidal stability and imparted to
nanoparticles the stealth towards macrophages, therefore a
prolonged blood circulation (29). The purified engineered AuNPs
can be concentrated at small volume (few hundreds of microliters)
resulting in samples characterized by a high concentration of
gold, which still maintain stability up to months of storage.
Noteworthy, this aspect is essential owing to the high amount of
gold necessary for setting each in vivo experiment. By an accurate
modulation of the relative amount of the reagents, we were able
to produce ‘one-pot’ quasi-spherical (AuNP2-AuNP4), spherical
(AuNP6, AuNP7) or anisotropic (AuNP9) functionalized gold
nanoparticles (Scheme 1 and Table 1).
AuNP2 and AuNP4, characterized by a quasi-spherical shape,
were synthesized as described (see Experimental part and SI,
Fig. 8 and 10 respectively), changing the capping ligand in the
final step of the synthesis (HS-PEG5000-COOH for AuNP2 and
Figure 1. Schematic representation of the synthesized AuNPs, obtained
by means of reductive reaction of HAuCl4 and stabilized with different
types of polyethylene glycol (PEG). Dimensions for star-shaped AuNPs
are referred to the core size.
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HS- PEG5000-OMe for AuNP4). The crystal structure correspond-
ing to Au metal is confirmed by the Electron Diffraction (ED)
(SI, Fig. 12). An improved control over dispersion and shape
was obtained by adjusting the reagents ratio and adding
glycerol in the growing step of the synthesis (28,30), affording
spherical samples AuNP6 (coated by HS-PEG5000-OMe) and
AuNP7 (coated by HS- PEG5000-CONHGlucose). AuNP6 (Fig. 2A)
is characterized by a median diameter of 15.8 nm±3.1 nm, while
AuNP7 (Fig. 6) by a median diameter of 16.6 nm±3.9 nm. Totally
anisotropic AuNP9 (Fig. 2B), characterized by the presence of
urchins and functionalized by HS-PEG5000-OMe (Scheme 1 and
Table 1), have been easily synthesized modulating the ratio of
the reagents during the second step of growth.
To evaluate the effect of the size for urchinated AuNPs, we
synthesized ‘one-pot’ functionalized gold nanostars by
exploiting the use of hydroquinone as unique reducing agent,
following a procedure reported in literature (31), yielding AuNPs
characterized by an enhanced core dimension (AuNP11, Table 1,
SI Fig. 11). Finally, gold nanoparticles were purified and fully
characterized in terms of morphology, composition, coating
functionalization and X-rays absorption (Table 1).
In Table 1, the ability of the colloidal gold solutions to absorb
X-rays is reported as Hounsfield Units (HU) measured in vitro by
micro-CT scan. The linear correlation between HU and gold
concentration suggests that X-rays absorption is not affected
by core morphology, size or surface coatings (see SI, Fig. 13).
2.2. In vivo CT imaging of functionalized gold
nanoparticles
Micro-CT imaging in live healthy mice were performed to
evaluate the biodistribution of AuNPs. Following intravenous
administration of gold nanoparticles, mice remained alive for
at least four hours from the injection and in most cases
(AuNP 4-6-9-11) up to 24 hours (sacrifice). We measured the
X-rays attenuation in the liver and in the blood pool within
the heart, to evaluate stealthness and prolonged persistence
in the blood of engineered AuNPs, comparing the behavior
of the different nanostructures (Fig. 3 and Fig. 4). Even if each
nano-system showed a high colloidal stability and an efficient
X-rays absorption, we identified AuNP6 and AuNP9 as the
most promising to act as efficient and safe CT contrast agents.
It can be noticed that AuNPs displaying carboxylic acids on
their surface (AuNP2 and AuNP3) were quickly internalized
in the liver, and after 1 hour from injection of these NPs, mice
displayed a high contrast in the liver. In the same way, the
nano-system characterized by the highest hydrodynamic
diameter (AuNP11) led to an important increase of liver contrast,
despite the lack of residual free charges on their surface.
These results can be better visualized in Fig. 4, which summa-
rizes the temporal trend of HU, expressed as heart/liver ratio,
over the time of observation. On the basis of the present results,
we do show that metal core anisotropy does not play any
Table 1. Description of engineered AuNPs, summarizing morphology, coating, hydrodynamic diameter (DH), Zeta-potential
(ζ-potential), gold concentration and X-rays attenuation of the solutions
Samples Morphology Coating DH (nm) ζ -potential (mV) [Au] mg/ml HU in vitro
AuNP2 Quasi-spherical HS-PEG5000-COOH 27.04 37.64 35.00 3378
AuNP3 Quasi-spherical HS-PEG5000-COOH/ HS-PEG5000-OMe 39.03 29.76 28.12 2304
AuNP4 Quasi-spherical HS-PEG5000-OMe 40.87 23.00 28.75 2376
AuNP6 Spherical HS-PEG5000-OMe 39.82 20.00 23.01 2062
AuNP7 Spherical HS-PEG5000-CONHGlucose 33.51 21.00 31.20 2453
AuNP9 Star HS-PEG5000-OMe 52.69 18.79 22.04 1834
AuNP11 Star HS-PEG5000-OMe 176.30 17.54 7.67 424
Scheme 1. Synthesis of AuNP 1–9. [HAuCl4] = 10mM; [AgNO3] = 5.9mM; PEG ligands: A: HS-PEG5000COOH (AuNP2); B: HS-PEG5000COOH/HS-
PEG5000OMe 1/1 (AuNP3); C: HS-PEG5000OMe (AuNP4, AuNP6, AuNP9); D: HS-PEG5000CONHGlucose (AuNP7). Abbreviations: Na3Ct = sodium citrate.
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significant role in CT imaging. At the same time, the anisotropic
gold nanoparticles (AuNP9) showed a very good X-rays absorp-
tion and a prolonged persistence in the blood, paving the way to
the development of innovative bimodal contrast systems.
To better delineate the in vivo behavior of these gold-based
nano-systems, we report in Fig. 5 the distribution over time of
contrast in coronal sections of three live mice, who received i.v.
infusion of a different AuNP batch each (i.e., AuNP3, AuNP6
and AuNP9). AuNP3 led to an immediate increase of liver
contrast, without appreciable changes in the contrast of the
heart, suggesting that AuNPs were immediately sequestered in
the liver. On the contrary, AuNP6 and AuNP9 led to an increase
of the heart contrast at five minutes, which remained almost
constant up to four hours, suggesting that AuNPs remained in
the blood pool.
2.3. Target-functionalized gold nanoparticles
Considering the importance of developing innovative contrast
agents, large efforts have been devoted to the production of
nano-materials able to selectively label the region of interest,
providing functional and morphological information (5,6). In this
contest, having in our hands a reliable method to synthesize
high quality and stable gold nanoparticles, we prepared
glucosamine-functionalized spherical AuNPs (AuNP7, Scheme 1
and Table 1). Stated their in vitro ability to act as CT contrast
agents, AuNP7 (Fig. 6) were selected as nano-tracer for the
active targeting against lung inflamed cells.
Figure 2. A. Left: TEM micrograph of AuNP6 sample. Right: statistical distribution of particles diameters: dmedian = 15.8 ± 3.1 nm; B. Left: TEM
micrograph of AuNP9 sample. Right: statistical distribution of branch length (inset of TEM micrograph) having minimum value 27.0 nm and maximum
value 100.9 nm. The median value was 54.2 nm (standard deviation of 13.6 nm).
Figure 3. Trend of HU values measured within the heart as a function of
the time after injection. In round brackets the dose (mg Au/Kg bw)
injected via tail vein for each experiment. The HU values at 0minutes cor-
respond to the contrasts within the heart before injection (basal value).
A. SILVESTRI ET AL.
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A group of 11 mice were treated with HCl, to induce a
chemical pneumonia and subsequently infused with a colloidal
solution of AuNPs. As shown in Fig. 7, the right lung (directly
injured by the acid) showed inflammation and hemorrhage,
while the left one did not have pathologic changes.
To evaluate in vivo AuNP7 behavior, a first injured mouse
received AuNP7 colloidal solution (230mg/Kg), showing that
nanoparticles were able to selectively track the presence of lung
inflammation. One hour after injection (see SI, Fig. 14), the
presence of AuNP7 circulating within the blood pool was
demonstrated by the high contrast within the heart and by the
progressive enhancement of the contrast in the lung region
affected by inflammation, indicating the uptake of AuNP7 by
inflammatory cells. After 4 hours of observation, the mouse was
sacrificed and lungs were removed and underwent a CT scan
in order to measure the contrast ex-vivo in the lung (Fig. 8A).
Figure 4. Heart/liver HU ratio measured 5minutes, 1 hour, 4 hours and 24 hours after AuNPs injection. In the round brackets the dose amount
(mg Au/Kg bw) injected for each experiment.
Figure 5. Coronal section of mice treated with AuNP3, AuNP6 and AuNP9. Baseline: images obtained before infusion. White arrow: liver; red
arrow: heart.
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Figure 6. AuNP7 used as functional CT contrast agents A) Left: TEM micrograph of AuNP7 sample. Right: statistical distribution of particle diameters:
dmedian = 16.6 ± 3.9 nm. B) Scheme of AuNP7.
Figure 7. Representative images of hematoxylin and eosin stained lung tissue sections of acid aspiration that showed the inflammatory and
serofibrinous exudate and hemorrhage in the right injured (A) lung, whereas no pathologic changes are observed in the left lung (B). (200X, scale
bar = 100 μm).
Figure 8. A. Computed Tomography imaging of the injured lung ex-vivo. The lesion at the right lung is clearly visible for its higher X-rays contrast
(HU right lung = 217; HU left lung = 42). B. TEM images of material collected by bronchoalveolar-lavage: AuNPs identified by black arrow and fragment
of pulmonary tissue identified by the white arrow.
Figure 9. Transaxial sections by computed tomography obtained in live, anesthetized mice with experimental pneumonia in the dorsal region of the
right lung (showed by the arrow), showing the distribution in time of AuNP7, after intravenous injection.
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To confirm the nanoparticles presence within the cells, a
bronchoalveolar lavage was performed three times in the right
(injured) lung and analysed by means of electron microscopy.
TEM images of the cellular samples let to show the presence of
nanoparticles within fragments of lung tissue (Fig. 8B), revealing
that they maintained their structure, with a median diameter of
32.5 ± 5.9 nm (32).
On the basis of these results, a new set of experiments was
carried out and 10 injured mice were treated with targeted and
non-targeted AuNPs, extending the time of animal observation
up to 24 hours after injection (dose used is reported in SI,
Tab. 1). Four mice have been treated with the control colloidal
solution of AuNP6 (coated by HS-PEG5000-OMe), while six mice
have been injected with targeted active AuNP7 (coated by
HS-PEG5000-CONHGlucose). Owing to the displayed glucose-
moiety, AuNP7 selectively accumulated in the lung inflamma-
tion, giving both anatomical and functional image information
(Fig. 9).
The AuNP6 and AuNP7 circulation in the blood was observed,
in the whole animal group (n = 10), up to 24 hours after injection
and it was possible to appreciate the increase of X-rays
contrast (Fig. 10) within the heart and in the site of lesion
(lung injury) (23).
Noteworthy, AuNP7 levels in the lung injury (right lung) were
higher if compared to AuNP6, even if this did not reach a
statistically significance. In the lung lesion, the AuNP7 remained
elevated up to 24 hours after injection, which indicates their
active accumulation, in contrast with the non-targeted ones.
This trend was not observed in other organs. In the heart, after
5minutes, the HU in mice treated with AuNP7 were higher but
in the following time points the two groups showed similar HU
levels. The AuNP liver’s uptake was modest in all animals,
confirming the stealthness of both nano-systems. The HU
increase in the bladder (observed in all animals) can be ascribed
to the small fraction of ultrasmall AuNPs, which can be filtrated
through the renal glomerulus, and highly concentrated in the
small volume of the bladder (32). To confirm this interpretation,
we collected urine samples after 1 hour from injection and we
analysed them by TEM microscope (see SI, Fig. 15). TEM images
show the presence of small AuNPs (d< 5 nm) whose numeral
and dimension were compatible with AuNP6 and AuNP7
histograms. After 24 hours from injection, mice were sacrificed
and organs (lungs and liver) were removed to quantify the
amount of gold accumulated within each. The removed organs
were then digested with aqua regia and the amount of metal
in each organ was measured by means of ICP-OES analysis. The
results, reported in Fig. 11, are consistent with the CT trend.
The metal accumulation in the lung injury (right lung) was higher
for mice treated with AuNP7 as compared to those treated with
the non-targeted ones (AuNP6). Left lungs, instead, show a
similar amount of gold both for mice injected with AuNP6 as
with AuNP7, highlighting how the glucosamine-functionalized
nanoparticles were selective towards the site of inflammation.
Figure 10. AuNP6 (n = 4) and AuNP7 (n = 6) contrast values measured within the heart, lung injury, liver and bladder at different time points
after injection.
Figure 11. ICP-OES analysis of liver and lungs of sacrificed mice after
24 hours from injection of AuNP6 (n = 4) and AuNP7 (n = 6). The abscissa
reports the amount of gold found in the organ (mg) normalized for the
dose injected to each mouse (mg Au/mg BW).
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3. CONCLUSIONS
In this work, we have been able to identify the nano-structures
which better respond to the requisite for acting as a good
pre-clinical contrast nano-agents. We presented a modified
protocol for the ‘one-pot’ production of functionalized shape-
controlled nanoparticles (from symmetric to anisotropic shapes).
Our protocols allowed to obtain reproducible and highly stable
engineered nanoparticles. AuNP6, AuNP7 and AuNP9 proved
to be excellent candidates as CT contrast agents, having an
increased blood-time permanence and a low uptake from the
reticuloendothelial system (RES). Nevertheless, no significant
differences were found when using anisotropic nanoparticles
as opposed to symmetric ones. Noteworthy, stable
glucosamine-functionalized AuNPs (AuNP7) proved to act as
efficient contrast agents targeted towards glucose uptake as
they accumulated preferentially in the lung injured by chemical
pneumonia in mice, in vivo. Further studies are currently
undergoing to evaluate organ toxicity and to better describe
the internalization of the gold nanoparticles in the cells and
how the uptake of glucosamine-functionalized particles reflects
the actual cellular glycolytic metabolism.
4. MATERIALS AND METHODS
4.1. Materials
All reagents were purchased from Sigma-Aldrich, unless men-
tioned otherwise, and used without further purification.
HAuCl4 · 3H2O was stored at 4 °C in the dark as 10mM solution.
AgNO3 solution (5.9mM) was freshly prepared before each syn-
thesis (avoiding the exposition to the light). HS-PEG5000-CH3O
and HS-PEG5000-COOH, purchased from Rapp Polymer GmbH,
were used as received and stored under dry argon atmosphere
at 20 °C. All glassware used for AuNPs synthesis was cleaned
with aqua regia (HCl(37%) / HNO3(65%) 3/1). Ultrapure deionized
water, MilliQ water, was used for the preparation of aqueous
solutions. Purification of AuNPs was performed by ultrafiltration
using Millipore Amicon Ultra-4 Centrifugal Filter Units with a
cut-off of 30 KDa. AuNPs were characterized by Dynamic Light
Scattering (DLS), using a 90 Plus Particle Size Analyzer from
Brookhaven Instrument Corporation (Holtsville, NY, USA) operat-
ing at 15mW of a solid-state laser (λ = 661 nm), using a scattering
angle of 90 °C. The Zeta-potential was determined at 25 °C using
a 90 Plus Particle Size Analyzer from Brookhaven Instrument
Corporation (Holtsville, NY, USA) equipped with an AQ-809 elec-
trode, operating at applied voltage of 120 V. UV/Vis spectra were
recorded on an Agilent 8453 instrument (Agilent Technologies,
Santa Clara, CA, USA). A disposable cuvette with 1 cm optical path
length was used for the measurements. FTIR spectra were
recorded using Thermo Nicolet NEXUS 670 FTIR spectrometer.
The samples were prepared as KBr pellets by titration with KBr
powder (1:100). Transmission Electron Microscopy micrographs
have been collected using TEM-Zeiss LIBRA 200FE, equipped with:
200 kV FEG, in column second-generation omega filter for energy
selective spectroscopy (EELS) and imaging (ESI), HAADF STEM
facility, EDS probe for chemical analysis, integrated tomographic
HW and SW system). The concentration of gold was determined
via Inductively Coupled Plasma-Optical Emission Spectrometers
(ICP-OES; iCAP 6300 Duo, Thermofisher). High resolution MALDI
were performed at CIGA (Centro Interdipartimentale Grandi
Apparecchiature, Milan, Italy), by means of MALDI tof-tof Autoflex
II instrument.
4.2. Synthesis of functionalized AuNPs
4.2.1. Synthesis of AuNP2, AuNP3 and AuNP4
A water solution of sodium citrate (3mL, 68mM), HAuCl4 · 3H2O
(2.5ml, 10mM) and AgNO3 (140μl, 5.9mM) were prepared and
stirred at room temperature for 6min. The pre-incubated
mixture was, then, added to a 500mL flask containing 250mL
of boiling water. The mixture stirred (750 rpm) for 1 h at 100 °C,
then the seeds solution was allowed to cool to room tempera-
ture. A second mixture of sodium citrate (16.5mL, 34mM),
HAuCl4 (12.5mL, 10mM) and AgNO3 (600μL, 5.9mM) was pre-
incubated for 6min and afterwards added to the seeds solution,
followed immediately by the addition of a solution of hydroqui-
none (13.3mL, 91mM). Then, the solution was allowed to age,
stirring at 750 rpm for 1 h. AuNP1 so obtained was directly used
without further purification or concentration. Under argon
atmosphere, 30mg of the suitable thio-PEG [HOOC-PEG5000-SH
(AuNP2) or 1:1 mixture of HOOC-PEG5000-SH/MeO-PEG5000-SH
(AuNP3) or MeO-PEG5000-SH (AuNP4) were dissolved in 5mL
of water containing 9mg of NaOH. Then, the PEG solution was
added to the mixture containing citrate-capped AuNP1 while
Argon was bubbling inside the solution (for 5minutes) and the
reaction mixture stirred for further 48 h at room temperature.
Functionalized AuNP2-4 were then concentrated and
purified by means of Amicon centrifugal Filter units to a final
volume of 700μL.
4.2.2. Synthesis of AuNP6 and AuNP7
A solution of sodium citrate (9mL, 68mM), HAuCl4 (7.5ml,
10mM) and AgNO3 (490μL, 5.9mM) were prepared and stirred
at room temperature for 6min. The pre-incubated mixture was,
then, added to a 500mL flask containing 250mL of boiling
water. After 1 h of mixing at 100 °C (750 rpm) the seeds solution
was allowed to cool at room temperature and 5mL of glycerol
was added. After 10min a second mixture of sodium citrate
(10mL, 34mM), HAuCl4 (7.5mL, 10mM) and AgNO3 (426μL,
5.9mM), pre-mixed for 6min, was added to the seeds solution,
immediately followed by a solution of hydroquinone (8mL,
91mM). Then, the solution was allowed to age, stirring at
750 rpm for 1 h. AuNP5 so obtained was directly used without
further purification or concentration. Under argon atmosphere,
30mg of the suitable thio-PEG [MeO-PEG5000-SH (AuNP6) or
HS-PEG5000CONHGlucose (see SI, AuNP7)] were dissolved in
5mL of water containing 9mg of NaOH. Then, the PEG solution
was added to the colloidal solution containing citrate-capped
AuNP5 while Argon was bubbling inside the solution (for 5minutes)
and the reaction mixture stirred for further 48h at room temperature.
Functionalized AuNP6 and AuNP7 were then concentrated and
purified by means of Amicon centrifugal Filter units to a volume
of 700μL.
4.2.3. Synthesis of AuNP9
A solution of sodium citrate (1.73mL, 68mM), HAuCl4 (1.46mL,
10mM) and AgNO3 (82μL, 5.9mM) were prepared and mixed
at room temperature for 6min. The pre-incubated mixture was,
then, added to a 1000mL flask containing 60mL of boiling
water. After 1 h of mixing at 100 °C (750 rpm) the solution was
A. SILVESTRI ET AL.
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cooled at room temperature and 54mL of glycerol and 600mL of
water were added. After 10min a second mixture of sodium
citrate (1.16mL, 34mM), HAuCl4 (13.4mL, 10mM) and AgNO3
(2.2mL, 5.9mM) pre-mixed for 6min, was added to the seeds
solution, immediately followed by a solution of hydroquinone
(5.3mL, 91mM). Then, the solution was allowed to age, stirring
at 750 rpm for 1 h. The bluish solution of AuNP8 was directly
used without further purification or concentration. Under argon
atmosphere, 30mg of MeO-PEG5000-SH were dissolved in 5mL
of water containing 9mg of NaOH. Then, the PEG solution
was added to citrate-capped AuNP8 solution while Argon was
bubbling inside the solution (for 5minutes) and the
reaction mixture stirred for further 48 h at room temperature.
Functionalized AuNP9 were then concentrated and purified
by means of Amicon centrifugal Filter units to a volume
of 700μL.
4.2.4. Synthesis of AuNP11 (31)
A solution of tetrachloroauric acid (7.5mL, 10mM) was diluted
with 200mL of water. Next, 6mL of an aqueous hydroquinone
solution (11mgmL1) was rapidly injected. The solution turned
from yellow to light blue almost instantaneously because of
the formation of gold nanostars. 30mg of MeO-PEG5000-SH
was added to the mixture to quench the reaction and cap the
AuNPs. Functionalized AuNP11 were then concentrated and
purified by means of Amicon centrifugal Filter units to a volume
of 700μL.
4.3. AuNPs characterization
The purification and concentration of AuNPs were performed by
centrifugation at 6000 rpm on filters with a cut-off of 30 KDa. The
solutions were filtered over 0.45μm minisart. Then the concen-
tration of the colloidal solution was completed, in Eppendorf
tubes at 14000 rpm, up to 700μL. TEM specimens were prepared
by dropping an aqueous solution of AuNPs onto on a carbon-
coated copper grid (300mesh) and evaporating the solvent.
The particle size distribution, in the spherical and quasi spherical
samples, was obtained analysing TEM images by the software
Pebbles (freely available from the http://pebbles.istm.cnr.it)
(33). Dimensions of star-shape nanoparticles have been
estimated by measuring the distance between diametrically
opposite branches using ITEM-TEM Imaging platform – Olympus
Soft Imaging Solutions. The number of measured nanoparticles
for each sample is around 250. UV/Vis spectra were recorded
on an Agilent 8453 instrument. DLS and ζ-potential measure-
ments were carried out on a Brookhaven 90 PLUS particles size
analyser. DLS samples were prepared by filtration with a
0.45μm cellulose acetate syringe filter before loading into the
cuvette in order to remove large interfering particulate matter.
Each sample was allowed to equilibrate for 3min prior to starting
measurement. Three to 10 independent measurements of 60 s
duration were performed, at 25 °C. The hydrodynamic diameter
calculations were performed using Mie theory, considering
absolute viscosity and refractive index values of the medium to
be 0.911 cP and 1.334, respectively. The Zeta-potential was
automatically calculated from electrophoretic mobility based
on the Smoluchowski theory. A viscosity of 0.891 cP, a dielectric
constant of 78.6, and Henry function of 1.5 were used for the
calculations. FTIR spectra samples were prepared as KBr pellets
by titration with KBr powder (1:100). The content of the metal
was determined by ICP-OES. Samples (1ml each) were digested
in a glass vial over a heating plate with aqua regia (2mL) for four
times. The dry residuals were dissolved in an HCl aqueous
solution 0.5M and properly diluted. The limit of detection (lod)
calculated for gold was 0.01 ppm.
4.4. In vivo CT analysis
CD1 mice (20–25 g) were obtained from Harlan Laboratories
(Udine, Italy) and kept under laboratory condition. Procedures
involving animals and their care were performed according to
the institutional guidelines which complied with national and
international laws and policies. The study was approved by the
ethical committee of our institution. We studied two sets of
animals, healthy (AuNP 3-4-6-9-11) and injured (AuNP6 and
AuNP7). The first set was aimed at screening and characterizing
AuNPs and one animal for each type of nanoparticle was used.
After the selection of the most appropriate AuNPs, the
experiments were repeated in four mice for AuNP6 and 6 mice
for AuNP7. Animals were anesthetized by using ketamine and
xilazine. Lung injury was induced by instillation of 1.5mL/kg
HCl 0.1M into the right bronchus through a small tracheal
incision (34). The bronchial catheter was removed and the
tracheal incision sutured. Animals were awakened and AuNPs
injection and imaging were performed 24 hours later to allow
the development of the inflammatory reaction. For imaging
healthy and injured anesthetized mice received PEG-capped
AuNPs (Au concentration depended on the batches, see to
Table 1, 200μL) injected via tail vein (i.v.) and underwent CT
scans (Skyscan 1176, Bruker, Kontich, Belgium) at different time
points (immediately before [baseline], five minutes, one and four
hours after injection). CT scanning lasted for about five minutes
(voltage 58 kV, current 431μA). Images were reconstructed with
a smoothing filter and corrected for ring artifact and beam
hardening. Reconstructed isotropic voxel size was 35μm3.
Images were reconstructed and analysed with the scanner
software (NRecon v.1.6.9 and CTAn v.1.13, Skyscan, Bruker,
Kontich, Belgium). For image analysis, we firstly calibrated
Hounsfield Units (HU) scale, by scanning a phantom made of
air and water, by ascribing the values 0 HU to water and
1000 HU to air. We then measured, at all time points, the den-
sity (in HU) on manually selected Regions of Interest (ROIs) on
the heart, liver and on the injured lung.
Sample preparation of bronchoalveolar lavage: 600μL of
lavage solution and cells were collected from right lung and
fixed in 2.5% glutaraldehyde and 4% paraformaldehyde. This
collected material was centrifuged and the resulted pellet was
suspended in equal volume of sodium alginate solution. Drops
of this cells/alginate suspension of 15μL were drown into a
Eppendorf-type micro-pipette and extruded firmly into a buffer
containing 0.1M calcium chloride pH 7.2. These drops were
included in Epoxy/Araldite resin, then the series of section were
prepared for the TEM analysis. For histologic examination, lungs
were fixed in 4% paraformaldehyde, then paraffin embedded
and stained with hematoxylin and eosin. The metal content in
lungs and livers was determined by ICP-OES. Samples of
homogenized organs in PBS solutions (1mL each) were digested
in a glass vial over a heating plate with aqua regia (2mL) for
10 times. The dry residuals were dissolved in a HCl aqueous
solution 0.5M and properly diluted. The limit of detection (lod)
calculated for gold was 0.01 ppm.
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